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Objectives: Deficit in visuospatial functions can influence both simple and complex daily
life activities. Despite the fact that visuospatial deficit was reported in schizophrenia,
research on visuospatial functions as an independent entity is limited. Our study aims
to elucidate the impact of visuospatial deficit in comparison with verbal deficit on global
functioning and quality of life in the first psychotic episode of schizophrenia spectrum
disorder (FES). The significance of clinical symptoms and antipsychotic medication was
also studied.
Methods: Thirty-six FES patients and a matched group of healthy controls (HC group)
were assessedwith a neuropsychological battery focused on visuospatial (VIS) and verbal
(VERB) functions. Using multiple regression analysis, we evaluated the cumulative effect
of VERB and VIS functions, psychiatric symptoms (PANSS) and antipsychotic medication
on global functioning (GAF) and quality of life (WHOQOL-BREF) in the FES group.
Results: The FES group demonstrated significant impairment both in VIS and
VERB cognitive abilities compared to the HC group. Antipsychotic medication did not
significantly affect either VIS or VERB functioning. PANSS was not related to cognitive
functioning, apart from the Trail Making Test B. In the FES group, the GAF score
was significantly affected by the severity of positive symptoms and VERB functioning,
explaining together 60% of GAF variability. The severity of negative and positive
symptoms affected only the Physical health domain of WHOQOL-BREF. The degree
of VERB deficit was associated with both Physical and Psychological health. Although
we did not find any relation between VIS functioning, GAF, and WHOQOL-BREF, a
paradoxical finding emerged in the Environment quality domain, where a worse quality
of the environment was associated with better VIS functioning.
Conclusions: Our results suggest that the deficit in VIS functions is an integral part
of cognitive deficit in schizophrenia spectrum disorders, rather than a side effect of
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symptomatology or antipsychotic medication. Moreover, VERB functioning was a better
predictor of GAF and WHOQOL-BREF than VIS functioning. Given the findings of
negative or missing effect of VIS deficit on WHOQOL-BREF and GAF, the accuracy of
these measures in evaluating the impact of global cognitive deficit on everyday life in
schizophrenia could be questioned.
Keywords: cognitive deficit, first psychotic episode, schizophrenia spectrum disorder, global functioning, quality
of life, visuospatial functions, verbal functions, antipsychotic medication
INTRODUCTION
Abnormalities in cognitive functions are considered to be one
of the key components in Schizophrenia (SZ). Neurocognitive
deficit represents a reliable feature, with moderate to large
effect size on global functioning across all cognitive domains
(Milev et al., 2005). An important amount of research in SZ
has examined the relationship between cognition and variety
of clinical factors including age of onset, symptomatology,
severity, duration, medication, functional outcome, and Quality
of life (QOL) (Heinrichs and Zakzanis, 1998; Bilder et al., 2000;
Mesholam-Gately et al., 2009). However, studies focusing on
specific relationships among cognitive domains or relationships
inside the domains and their influence on daily functioning are
limited (Harvey et al., 2012). One of the most neglected areas
is the comparison of the impact that visuospatial (VIS) and
verbal (VERB) abilities have on global functioning and QOL.
Focused research of VIS functions can help provide a better
understanding of neuropsychological patterns of heterogeneity in
SZ. In addition, since VIS functions are less biased by language
skills, research in this area can enlarge the neuropsychiatric field
(Paradis, 2008). Furthermore, VIS functions are an important
tool for a comparative research on animal models of SZ
(Fajnerová et al., 2014).
One of the main reasons why visuospatial functions did
not receive much attention as an independent entity in the
research of SZ was the negative impact of the first-generation
(typical) antipsychotic treatment on somemotor and visuospatial
functions (e.g., psychomotor retardation; Spohn and Strauss,
1989; Bilder et al., 1992; Meltzer and McGurk, 1999; Arana,
2000). With the development of second generation (atypical)
antipsychotics (AP), the risk of neurological side effects seemed
reduced. Moreover, findings of slightly positive effects of some
atypical AP on cognitive deficit were reported in SZ (e.g.,
Peuskens et al., 2005; Houthoofd et al., 2008) and these findings
were supported by results in an animal model of SZ (Bubeníková
et al., 2005). However, when atypical antipsychotics were directly
compared with the typical ones, no differences were found in
either psychomotor functions or other cognitive areas (Jones
et al., 2006; Keefe et al., 2007; Lewis and Lieberman, 2008).
Another limitation related to the study of VIS functions is that
not all studies use a separate model of verbal and visuospatial
functions. Usually, both VERB and VIS functions are included
in the same cognitive domain (e.g., memory domain) or in
the total IQ score; alternatively, they are studied as isolated
variables. The question how much (if at all) the AP medication
affects the motor and VIS functions when compared with the
verbal functions, and to what extent the visuospatial functions
impact daily functioning and the quality of life requires more
research.
Visuospatial impairment can negatively affect various daily
activities from the most common, such as watching TV or
reading a book, to themost complex, including social interactions
(visual recognition of social signals), and recognition of territorial
boundaries (interpersonal space; Cummings and Mega, 2003).
SZ subjects exhibit impaired performance in a wide range of
VIS functions, from the most basic level of visual perception to
more complex visuospatial processing and navigation abilities
(e.g., Stuve et al., 1997; Doniger et al., 2001; Butler et al., 2005;
Hanlon et al., 2006; Piskulic et al., 2007; Weniger and Irle,
2008; Cocchi et al., 2009; Folley et al., 2010; Landgraf et al.,
2010; Fajnerová et al., 2014). This decline in VIS performance
is already present in the first episode of schizophrenia and
performance further deteriorates over time, predicting poor
outcome (Stirling et al., 2003). Cross-sectional studies in subjects
with late-life schizophrenia report the impairment in visuospatial
ability, alongside with the executive and verbal fluency deficit.
Moreover, longitudinal studies suggest that the cognitive decline
in late-life schizophrenia may first affect VIS abilities (Rajji and
Mulsant, 2008). It was also demonstrated that VIS tasks related
to attention, memory, and planning predict improvements
on psychosocial functions, such as autonomy in daily living,
treatment compliance, and social competence in subjects with
psychosis (Prouteau et al., 2005). Given the significance of VIS
functions in our daily life, it is expected that visuospatial tests
would be good predictors of functional outcome in SZ.
Functional capacity and quality of life play a key role in
the study of the course, treatment efficacy, and other factors
related to functional outcome in SZ. Both functional capacity
and QOL are negatively associated with clinical symptoms
(Gaite et al., 2005; Malla and Payne, 2005; Milev et al., 2005;
Makara-Studziñska et al., 2011). Negative symptoms are more
strongly related to poor QOL and psychosocial functioning in
SZ outpatients (Eack and Newhill, 2007; Rocca et al., 2009),
whereas general psychopathology shows a consistent negative
relationship with QOL across all study samples and treatment
settings (Eack and Newhill, 2007; Rocca et al., 2009). Findings
about the influence of positive symptoms are heterogenous, with
the relationship toward negative and general symptomatology
being more evident, varying only in the extent of impact (Eack
and Newhill, 2007; Rocca et al., 2009).
In terms of cognition, the current state of the literature did
not enable drawing any conclusions about specific cognitive
constructs related to global functioning and QOL. Some studies
have documented a relationship between measured general
cognitive ability (IQ index) and global functioning or QOL
Frontiers in Behavioral Neuroscience | www.frontiersin.org 2 December 2015 | Volume 9 | Article 322
Rodriguez et al. Visuospatial Functions in Schizophrenia
(Tzeng et al., 2004; Chaplin et al., 2006; Leeson et al.,
2009), while other studies also point out the importance of
specific neuropsychological domains. Results of these studies are
very heterogeneous, depending on the measures used in the
assessment. Despite the heterogeneity of measures, the deficit
in executive functions appears to be the most evident and
burdensome, and is most related to the impairment of global
functioning and QOL in SZ (Bilder et al., 2000; Reed et al., 2002).
In addition, lower QOL is related to the deficit in verbal memory
(Ritsner, 2007; Fiszdon et al., 2008; Matsui et al., 2008). As was
stated previously, VIS and VERB functions are usually combined
in a single domain or IQ score. Thus, the role of VIS functions in
global functioning and QOL remains unclear.
To our knowledge, no study to date has described the extent
to which visuospatial functions affect everyday life of SZ patients,
in contrast to the effect of verbal abilities. Our study aimed to
answer the following questions:
(1) Are visuospatial abilities impaired in the first-episode
schizophrenia spectrum (FES) patients in comparison with
the matched group of healthy controls? If that is the case, is
the degree of the deficit the same as in verbal functions?
(2) Are the VIS functions in FES patients affected by
the antipsychotic medication and the actual psychiatric
symptomatology (measured with PANSS)? Is similar effect
visible in the VERB functions?
(3) Is the global functioning and the quality of life in FES
patients affected by VIS functioning when analyzed in the
presence of VERB functions and clinical characteristics
(symptoms and medication dose)? If so, is the effect of
visuospatial and verbal functioning the same?
MATERIALS AND METHODS
Subjects
Thirty-six subjects (22males and 14 females, FES group) whomet
ICD-10 criteria for the first psychotic episode of schizophrenia
spectrum disorder [F20.X (N = 4) and F23.1/F23.2 (N =
32)] were recruited at the National Institute of Mental Health
(NIMH). Patients were evaluated once they were stabilized
at the end of their first psychiatric hospitalization in partial
symptomatic remission state, according to Andreasen’s remission
criteria (2005). The group was considered in partial remission
state rather than in complete remission, as they did not
fulfill the criterion of asymptomatic 6-month period. Study
subjects were diagnosed in a routine clinical process by two
experienced psychiatrists. In case of diagnostic disagreements
(e.g., comorbidity) the specific case was excluded from the study.
In order to compare the cognitive performance in FES
subjects with the healthy population, a group of healthy control
subjects (N = 36, group HC) was recruited from the same
socio-demographic background via a local advertisement. The
inclusion criteria for both groups were: (a) 17–35 years of age;
(b) no history of neurological disease or loss of consciousness
longer than 10min; (c) native in Czech/Slovak language; and (d)
additionally for the FES group to meet ICD-10 diagnostic criteria
(dg F20.X or F23.1, F23.2) and to be first admitted to psychiatric
care. The main exclusion criterion for the control subjects was
personal history of any psychiatric disorder; for the FES group
it was the fulfilled diagnostic criterions for another psychiatric
disorder. Both groups were carefully matched in terms of sex,
age (max 2 years difference tolerance), and level of education (for
details and statistical comparison of the matching parameters,
see Table 1). In each group there were 16 participants with a
higher education level (university studies) and 20 with a lower
level of education.
Prior to the study, all participants signed a written informed
consent in accordance with the Declaration of Helsinki, approved
by the Ethics Committee of NIMH.
Clinical and Neuropsychological
Assessment
Two psychiatric scales were used to evaluate clinical
characteristics in the FES subjects. Current symptomatology
TABLE 1 | Demographic data, clinical assessment, and QOL questionnaire.
Demographic
variables
Group mean ± SD Group differences
FES HC Mann–Whitney U p-value
N 36 36
Sex (M:F) 22:14 22:14
Age 26.3 ± 5.6 25.7 ± 5.2 614 0.697
Education level (1–6) 3.7 ± 1.3 4.0 ± 1.2 556 0.261
Clinical assessment FES subjects
(mean ± SD)
PANSS total score 50.8 ± 17
PANSS-positive 12.5 ± 5.2
PANSS-negative 16.0 ± 7.3
PANSS-general 26.4 ± 6
AP medication—CPZ
equivalents (mg)
391.2 ± 122
GAF 64.5 ± 18.3
WHOQOL-BREF FES subjects
(mean ± SD)
Normative data
(mean ± SD)
(Dragomirecká and
Bartonˇová, 2006b)
Physical health
(domain 1)
14.4 ± 2.4 15.5 ± 2.6
Psychological health
(domain 2)
14.1 ± 2.5 14.8 ± 2.4
Social (domain 3) 13.2 ± 3.1 15.0 ± 2.9
Environmental
(domain 4)
14.3 ± 2.1 13.3 ± 2.1
First psychotic episodes of schizophrenia spectrum disorder subjects (FES) and healthy
controls (HC) individually matched by sex, age (within 2 years), and education level (see
demographic variables). All values are present as mean ± SD. Clinical scales PANSS
(Positive and Negative Symptoms Scale) and GAF (Global Assessment of Functioning),
antipsychotic medication level in CPZ (chlorpromazine) equivalents, and Quality of life
questionnaire WHOQOL-BREF assessed in FES subjects. Education level: 1, less than
high school; 2, started high school; 3, completed high school; 4, started university; 5,
completed university; 6, started postgraduate studies.
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was assessed using the Positive and Negative Syndrome Scale
(PANSS; Kay et al., 1987). The Global Assessment of Functioning
(GAF; Jones et al., 1995) was used in order to objectively evaluate
general psychosocial functioning of the FES group. The GAF
scale is used to address general functioning (score 0–100) in
daily activities of individual FES subjects. All FES subjects were
medicated by different dose and type of atypical antipsychotics
or their combination (olanzapin, amisulpirid, and risperidon),
that is why chlorpromazine equivalents (CPZ; Woods, 2003;
Andreasen et al., 2010) were used to evaluate the effect of
medication dosage on cognitive functioning. For details on the
clinical parameters see Table 1.
The quality of life was subjectively evaluated by FES subjects
using the Quality of life questionnaire WHOQOL-BREF (WHO
group, 1998), a short-form quality of life assessment that
calculates four domain profiles (Physical health, Psychological
health, Social relationships, and Environment), and was
validated for FES population (Mas-Expósito et al., 2011).
The questionnaire was translated and validated for a Czech
population (Dragomirecká and Bartonˇová, 2006b).
Regarding the neuropsychological assessment, the used
measures were chosen in accordance with the evidence of
related articles (mentioned in introduction) and suggested also
by the MATRICS initiative (Green et al., 2004; Nuechterlein
et al., 2008). Some additional measures not commonly used
and standardized in schizophrenia population were used in
order to assess VIS functions in greater detail. The final
neuropsychological battery consisted of 11 tests focused on
both the visuospatial and the verbal functions (see Table 2). All
tests were assessed by trained clinicians, according to the cited
administration protocols. Detailed information about all test
methods is provided in Table 2. In order to compare cognitive
TABLE 2 | Description of (A) Visuospatial and (B) Verbal neuropsychological tests.
Test Monitored cognitive function Test outputs References Test description
(A) VISUOSPATIAL NEUROPSYCHOLOGICAL TESTS
Trail Making Test (TMT A
and B)
Psychomotor speed (A);
visuospatial working memory (B);
mental flexibility (B/A)
Time A (s); Time B (s); Ratio B/A Reitan and Wolfson, 1985;
Preiss and Preiss, 2006
Chaining a sequence of numbers
(A) or alternatively numbers and
letters (B) that are randomly
distributed on a single paper
Rey-Osterrieth (Taylor)
Complex Figure Test (RCFT)
Visuospatial organization,
constructional functions and
visual memory
Raw score for copy trial (RCFT-copy),
reproduction after 3 (RCFT-3) and
30min (RCFT-30)
Osterrieth, 1944; Preiss
et al., 2012
Copy and reconstruction of
figure after 3 and 30min
Key Search Test (KST) Executive functions Raw scores of strategy BADS (Wilson et al., 1996) Strategy of exploration of
2-dimensional space (2D square
shape)
Money Road-Map Test
(RMT)
Spatial orientation Raw scores for number or errors/32;
A, B and C error types
Money et al., 1965 Ability to determine right/left
turns on crossroads in 2D view
of a simple maze/city
Spatial Span (SS) Visuospatial working memory Raw scores: total (forward +
backward)
PC version adjusted from
the Corsi block test in
(PEBL, 2012) according to
WMS-III (Wechsler, 1997)
Repeating a sequence of spatial
positions presented in 2D plane,
forward or backward
PEBL Perceptual Vigilance
Task (PVT)
Vigilance and attention Number of lapses [Reaction time (RT)
over 500ms], average RT speed
PEBL battery (PEBL, 2012;
Dinges et al., 1985; Loh
et al., 2004)
Response to stimulus appearing
in the variable time interval
(1–9 s) during 10min
(B) VERBAL NEUROPSYCHOLOGICAL TESTS
Auditory Verbal Learning
Test (AVLT)
Verbal learning and memory Learning curve and total number of
words (AVLT-I-V); immediate recall
(AVLT-VI); delayed recall (AVLT-30);
number of confabulations and
repetitions
Rey, 1964; Preiss et al.,
2012
Repeated recall of 15 words with
interference trial (B) and delayed
recall after 30min
Verbal Fluency Test (VFT) Psychomotor speed and mental
flexibility
Number of words for phonemic (total
of three trials) and semantic fluency
Preiss et al., 2012 Speaking aloud words beginning
with letters N, K, P or naming
category of animals during 1min
Digit Span (DS) Attention (forward), verbal
working memory (backward)
Raw scores: total (forward +
backward)
WAIS-III (Wechsler,
1997); Czech version
(Cˇernochová et al.,
2010)
Repeating list of numbers
forward and backward
Similarities (Sim) Verbal conceptualization Raw score–correct responses Describe similarities between
pair of words
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performance in the FES subjects with the healthy population, the
same test battery was administered to a HC subjects. Below is
a description of the three visuospatial methods that have some
specific characteristics.
The PEBL (PEBL, 2012) version of the Perceptual Vigilance
Task (PVT) was used in its 10-min-long alternative (Loh et al.,
2004) in order to test attention and vigilance. A simple circle
stimulus appears in the PVT at intervals ranging between 2 and
12 s, and the participant is required to press the spacebar as
quickly as possible.
A computerized version of the Spatial Span (SS) test was used
in order to test spatial attention and working memory without
uncontrolled examiner effects (such as prolonged presentation of
the longer spatial sequences). We adjusted the original protocol
of the Corsi block-tapping test (Kessels et al., 2000) applied in
the PEBL battery (PEBL, 2012) to match individual positions
and spatial sequences of the SS in the WMS-III (Wechsler, 1997;
Cˇernochová et al., 2010).
The Money Road-Map-Test (Money et al., 1965) is not
traditionally used in standard test batteries such as MATRICS;
this test was selected in order to test specific visuospatial
functions, such as mental rotation and perspective taking
strategy. For this reason, the total number of errors (out
of a total of 32 turns) was divided into three categories
(according to Marková et al., 2015) by the angle of the
route before each turn relative to the subject’s heading:
(A) rotation of <70◦ (9 turns), (B) rotation of 90◦ (13
turns), and (C) rotation of more than 110◦ (10 turns).
Another specifically selected test, the Key Search Test, was
chosen as a sensitive method testing dysexecutive syndrome
in schizophrenia (Evans et al., 1997), using spatial planning
abilities.
Data Analysis
Statistical analysis was performed using the SPSS software
(version 15.0). The significance level of all statistical analysis
was set to 0.05. The group differences in demographic variables
(age, education) were analyzed using non-parametric Mann–
Whitney U-test. Identical method was used to compare the
raw scores obtained in the visuospatial tests. Non-parametric
Spearman Rank Order Correlations were used in order to detect
correlations between variables.
The raw scores of neurocognitive tests were used to compare
performance between the FES subjects and the HC. Raw
scores were transformed to z-scores in order to calculate
cumulative scores of VERB and VIS scores. Z-scores were
calculated as the difference among raw scores of the individual
FES subjects and the HC group mean, divided by the HC
standard deviation. The cumulative scores (VERB and VIS) were
computed as a sum of the standardized z-scores divided by
the number of applied measures from the relevant variables
list as follows (for explanation of individual abbreviations see
Table 2): VERB score (AVLT_I-V, AVLT-VI, AVLT-30, VFT-
semantic, VFT-phonemic, DS-backward, Similarities) and VIS
score (RCFT-copy, RCFT-3, RCFT-30, TMT-A, TMT-B, SS-
backward, RMT-total errors). PVT test results were not included
in calculation of the cumulative scores, as performance on
this test is purely attentional. In addition, to assure the
accuracy of input variables to the cumulative scores and
their consistency, reliability analysis and factor analysis were
performed (Cronbach’s Alpha for VERB = 0.73; Cronbach’s
Alpha for VIS = 0.75). Multiple linear regression analysis
(stepwise method criteria as follows: probability-of-F-to-enter
≤ 0.05; probability-of-F-to-remove ≥ 0.10) was used to assess
the effect of performance in individual visuospatial and verbal
tests (dependent variables) of (A) the clinical characteristics
(independent variables): PANSS (scores divided into three sub-
scores: general symptoms–G, positive symptoms–P, negative
symptoms–N), and (B) the antipsychotic medication calculated
in CPZ. In additional stepwise multiple linear regression
analysis an overall effect of PANSS scores, CPZ level, and
cumulative VERB and VIS scores was assessed on (A) global
functioning measured by GAF and (B) four individual domains
of quality of life measured by WHOQOL-BREF (WHO group,
1998).
RESULTS
Differences in Cognitive Performance
Between FES and HC Group
As a result of matching the participants on an individual basis, no
significant group differences in age and education were observed
(Figure 1 and Table 1). In each group, there were 16 participants
with a higher education level (university studies) and 20 with
lower level of education.
Group differences in the results of neuropsychological
tests were significant in most of the applied VIS and
VERB measures, when analyzed from raw scores using the
non-parametric Mann–Whitney U-test (for more details see
Tables 3A,B).
The group of FES subjects showed significantly lower VIS
performance on all three parts of the Rey-Osterrieth Complex
Figure Test (RCFT-copy, RCFT-3, RCFT-30). The FES group was
also slower in the Trail Making Test part A and part B. The
average speed of FES subject responses in the PVT was lower
and they also had a higher number of lapses (with reaction times
above 500ms). The FES subjects also made more errors on the
Road Map Test (RMT). In addition, splitting of individual turns
in the RMT (according to Marková et al., 2015) to three possible
error types showed that schizophrenia subjects tend to fail more
in the turns demanding mental rotation of the spatial scene
(turns B and C) compared to the turns that demand no or very
small mental rotation (see Figure 2). We found no significant
differences in the raw scores of the KST from the BADS battery.
In contrast to the Digit Span (DS) test, the SS test did not
show any significant group differences. However, the difference
observed in the backward score was approaching the significance
level (p = 0.063).
VERB performance was significantly impaired in most of
the VERB measures as follows: verbal learning and delayed
recall in the Verbal Learning Test (AVLT); the phonemic and
semantic Verbal Fluency (VFT), abstract executive functions in
the Similarities (Sim) and working memory in the DS task. No
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FIGURE 1 | Neuropsychological profile of FES subjects calculated in z-scores for individual test parameters relative to the healthy controls (average
Z-score = 0). Selected test results are divided into verbal (left) and visuospatial (right) tests. FES, first psychotic episodes of schizophrenia spectrum disorder; HC,
healthy controls; VFT, Verbal Fluency Test; AVLT, Auditory Verbal Learning Test; DS, Digit span; PVT, Perceptual Vigilance Test; TMT, Trail Making Test; RMT, Money
Road-Map Test; RCFT, Rey-Osterrieth Complex Figure; SS, Spatial span; KST, Key Search Test.
difference was observed in the immediate recall and attention
performance in DS forward.
Regression Model of PANSS Effect on
Performance in Visuospatial and Verbal
Tests in FES
First set of stepwise multiple regression analysis models
of psychiatric symptomatology measured using PANSS
(predictors: PANSS-P, PANSS-N, PANSS-G) showed no
effect of symptomatology on the performance in individual
visuospatial and verbal tests (dependent variables), except for the
performance in one single test—the Trail Making Test part B.
Two of the three predictors from the regressionmodel performed
by stepwise method were significant: PANSS-N and PANSS-G.
They explained more than 40% of performance variability in the
TMT-B test (see Table 4). No effect of individual PANSS scores
was identified on cumulative VERB and VIS scores.
Regression Model of CPZ Level Effect on
Performance in Visuospatial and Verbal
Tests in FES
We did not observe any significant influence of medication
(CPZ) on the performance in any of the visuospatial tests using
the linear regression analysis. We identified negative effect of
medication dosage (B = −0.040, SE = 0.017, Beta = −0.373)
only in one verbal test—the phonemic Verbal Fluency Test (N =
35). CPZ explained 11% of performance variability (SE = 12.253,
Durbin-Watson= 2.247; F = 5.338, p < 0.05). This observation
would not survive Bonferroni adjustments (p = 0.027). No effect
of CPZ level was identified on cumulative VERB and VIS scores.
Regression Model of Clinical and
Neuropsychological Factors on Global
Functioning in FES
In order to analyze the possible effect of verbal and nonverbal
cognitive performance on global functioning (measured on the
GAF scale), we performed a multiple regression analysis with
the following predictors: PANSS-P, PANSS-N, PANSS-G, CPZ
level, and cumulative VIS and VERB scores (see Table 5).
Only two of the independent variables, the severity of positive
symptoms (PANSS-P score) and verbal functioning (cumulative
VERB score), showed a significant effect on global functioning.
Together, these variables explained more than 60% of GAF
variability.
Regression Model of Clinical and
Neuropsychological Factors on Quality of
Life (QOL) in FES
The same model of clinical and neuropsychological parameters
was applied in the stepwise multiple regression analysis that
identified significant effect of severity of negative symptoms
(PANSS-N score), verbal functioning (cumulative VERB score)
and positive symptoms (PANSS-P score) on perceived quality
of Physical health (domain 1) in FES. These predictors together
explained nearly 50 % of the observed variability (for details
see Table 6). The QOL domain Psychological health (domain 2)
was found to be affected by the overall VERB functioning (see
Table 7).
No significant effect of clinical and neuropsychological
parameters was observed in the evaluated quality of Social
relationships (domain 3). In contrast, the Environment quality
(domain 4) appeared to be affected mostly by one significant
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TABLE 3 | Group differences in (A) Visuospatial and (B) Verbal neurocognitive tests.
Neurocognitive assessment FES raw scores (N = 36) HC raw scores (N = 36) Mann–Whitney U p-value
mean SE median SD mean SE median SD
(A) VISUOSPATIAL PERFORMANCE
TMT–A 38.3 2.1 35.5 12.5 27.8 1.6 26.5 9.4 306.5 <0.001***
TMT–B 93.5 7.6 84.5 45.4 50.6 2.1 49.5 12.8 181 <0.001***
Ratio B/A 2.5 0.1 2.3 0.8 1.9 0.1 1.9 0.5 417 <0.01**
RCFT–copy 32.5 0.5 33.5 3.0 35.6 0.1 36 0.9 201 <0.001***
RCFT–3min 18.8 1.1 22.0 6.5 25.7 0.9 26 5.2 234 <0.001***
RCFT–30min 19.3 1.1 19.8 6.4 25.8 0.8 26 4.6 237 <0.001***
Recognition (errors) 4.6 0.4 4.5 2.1 3.6 3.0 0.3 1.9 360 0.073
KST 11.9 0.6 12.5 3.4 13.2 0.2 13 1.5 532.5 0.188
RMT–number of errors/32 3.1 0.6 2 3.6 1.2 0.4 0 2.4 394 0.003**
RMT A 0.3 0.1 0 0.8 0.1 0.1 0 0.5 628 0.661
RMT B 1.6 0.3 1 1.8 0.8 0.3 0 1.7 457.5 0.021*
RMT C 1.2 0.3 1 1.7 0.3 0.1 0 0.8 385 <0.001***
SS total 16.3 0.5 17 3.1 17.6 0.4 18 2.3 460 0.147
SS forward 8.6 0.3 9 1.6 8.9 0.2 9 1.4 535 0.592
SS backward 7.8 0.4 8 2.1 8.7 0.2 9 1.5 429 0.063
PVT–average response speed 337.3 8.7 321 44.5 305.5 8.0 294.5 40.8 189.5 0.007**
PVT–correct 66.3 1.8 70 10.0 70.7 0.8 72 4.9 415 0.068
PVT–comissions 1.3 0.4 0 2.5 0.9 0.2 0 1.3 541 0.791
PVT–lapses 7.9 1.6 4 9.1 2.1 0.6 1 3.6 279.5 <0.001***
(B) VERBAL PERFORMANCE
AVLT—I-V 47.8 1.8 48.0 10.8 59.9 1.2 61.5 7.5 231.5 <0.001***
AVLT—3min 9.3 0.4 9.0 2.5 13.1 0.3 14.0 2.1 157.5 <0.001***
AVLT—30min 8.6 0.5 8.0 3.0 13.1 0.4 14.0 2.2 137.5 <0.001***
AVLT–repetitions 6.0 0.8 4.5 5.0 1.9 0.4 1.0 2.2 302.5 <0.001***
AVLT–confabulations 2.0 0.4 1.0 2.5 1.1 0.3 1.0 1.6 543.5 0.214
VFT phonemic 41.8 2.2 41 12.9 48.9 1.7 48.5 10.4 395.5 0.004**
VFT semantic 19.7 1.0 18.5 5.6 28.9 0.9 28.0 5.5 120 <0.001***
DS total 14.8 0.7 14.5 4.5 17.0 0.7 17.0 3.9 450 0.025*
DS forward 9.3 0.4 8.5 2.2 9.7 0.4 9 2.3 573 0.392
DS backward 5.2 0.4 6 2.1 7.4 0.4 7.5 2.3 397 0.004**
Similarities 22.9 0.8 23 4.9 28.8 0.4 29 2.2 165 <0.001***
SE, standard error of the mean; SD, standard deviation. For abbreviations of individual methods see Table 1. TMT, Trail Making Test; RCFT, Rey-Osterrieth Complex Figure; KST, Key
Search Test; RMT, Money Road-Map Test (A, B, C—type of errors); SS, Spatial Span; PVT, Perceptual Vigilance Test; AVLT, Auditory Verbal Learning Test; VFT, Verbal Fluency Test; DS,
Digit Span. Significance level: *p < 0.05, **p < 0.01, ***p < 0.001.
parameter, the cumulative VIS score performance. This factor
explained together with CPZ level around 27% of the
observed variability in domain 4 (see Table 8). However, worse
Environment QOL was predicted by better VIS functioning and
higher AP dosage.
DISCUSSION
Differences in Cognitive Performance
Between FES and Control Group
Our study confirmed the presence of a deficit in visuospatial
cognitive abilities in a sample of first psychotic episode of
schizophrenia spectrum disorder subjects, when compared with
matched group of healthy controls. Similar pattern of deficit was
also observed in verbal functions. This result is in accordance
with previous studies, both in the first episodes and chronic SZ
subjects (e.g., Green et al., 2004; Fioravanti et al., 2005). First, we
selected the PVT as an indicator of vigilance and response speed,
as deficits in these abilities could affect performance in other
applied measures. Our sample of FES subjects demonstrated
deficit in vigilance and response speed on the PVT task. However,
this deficit ranged between none and moderate (SD 0–1.5),
with more severe deficits observed in other cognitive measures.
Nevertheless, we suggest future visuospatial studies apply such
attentional measure as a covariate factor in order to clarify
how vigilance and response speed may affect tested visuospatial
abilities.
Deficit on visuospatial functions was manifested in perceptual
organization abilities (copy in the Rey-Osterrieth Complex
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FIGURE 2 | Group performance presented as number of errors on the
Money Road Map Test (RMT) (mean ± standard error). Errors are divided
into three different types according to the rotation toward subjective
perspective of the tested subject (A–less than 70◦ deviation from subject’s
heading; B–90◦; C–more than 110◦). FES group, first psychotic episodes of
schizophrenia spectrum disorders; HC group, healthy controls. Significance;
ns, non-significant; *p < 0.05, ***p < 0.001.
Figure Test- RCFT) and in the delayed recall of visuospatial
information (RCFT after 3 and 30min), while the recognition
(RCFT recognition) of visuospatial material was comparable with
the performance of HC. This finding was characterized by a
reduced number of recalled details but not by an increased rate
of forgetting. This is consistent with a disturbance in encoding
or retrieval from memory but no deficit in information storage
(Rodriguez, 2012). The problems in recall might be further
compounded by a primary deficit in visual scanning abilities or
limited analysis of the visual fields, leading to the omission of
significant details and even whole sections of the figure (Golden
et al., 2002).
Trail Making Test (TMT-A and B) also showed significantly
slower processing speed, impaired visuomotor tracking and
switching ability. Although the performance on the TMT might
be perceived as partly language dependent, since the sequence
of numbers or numbers and letters has a verbal component,
participants’ visuospatial tracking ability is the main cognitive
domain assessed by this task. The higher ratio of TMT B/A
also pointed out a deficit in executive control function (Lezak
et al., 2012). The repeated finding of significantly impaired
TMT A and B performance in SZ (Heinrichs and Zakzanis,
1998), complemented by the TMT ratio B/A deficit, suggests
an independent deficit in both processing speed and switching
ability. Similar to the RCFT, the problems on both these functions
might be further compounded by a primary deficit in visual
scanning abilities. Future research in this area is needed.
Interesting results were found in the Money Road Map Test
(RMT), which to our knowledge has not been previously used
in FES patients. The higher number of total errors shows deficit
in left/right direction sense, and additionally in perspective
taking abilities (Schultz, 1991; Marková et al., 2015). These
abilities are suggested as the main solution strategy in RMT.
The lower RMT performance in FES group is therefore even
more apparent, if the individual intersections are divided into
three types according to their perspective taking demands, which
is essential in order to respond in the left/right condition.
While the number of errors in condition A (no change in
perspective) is not significantly disrupted in FES, both conditions
B and C (90 and more degrees deviations requiring perspective
taking) showed significant impairment. On top of that, the
number of errors increased with the growing degree of deviation
(from condition A–C), similarly to the mental rotation abilities
described previously (e.g., de Vignemont et al., 2006). This
finding deserves further investigation and standardization of the
method that could lead to a wider usage of this test in SZ clinical
research. Moreover, due to its spatial characteristic the test could
also be very useful in comparative studies of SZ.
The visuospatial executive planning ability, measured with
the Key Search Test (KST), failed to show a deficit in FES
subjects. Impairment in KST was previously demonstrated in
studies of chronic SZ (Evans et al., 1997; Ihara et al., 2003; Vargas
et al., 2009). The fact that we evaluated first psychotic episode
of schizophrenia spectrum patients in early remission could
explain this contradictory finding. Ihara et al. (2003) showed
connection between the KST performance and the severity of
negative symptoms in chronic SZ subjects. The mild severity of
negative symptoms in our FES group could be responsible for the
lack of significance found in KST. The lack of information about
the symptomatology in the other two cited studies does not allow
us to properly compare our findings. In addition, the fact that
the differences were analyzed using the raw scores (0–16) could
cause smaller sensitivity of the KST measure, as the recalculated
profile scores (range 0–4) separate the performance more strictly
into five categories. To test this presumption, we did an ex post
facto analysis with raw scores transposed to profile scores, which
indeed led to significant disadvantage of the FES group (U = 445;
p = 0.023).
Verbal abilities showed a deficit in conceptualization
and executive functions (semantic Verbal Fluency Test and
Similarities), and in verbal learning and delayed recall (AVLT).
It would be interesting to also analyze the verbal recognition
pattern and compare it to the results of visuospatial recognition.
Studies addressing this topic in SZ showed that the verbal
recognition is preserved (see Fiszdon et al., 2008). However,
because of some missing data in verbal recognition of HC group
we were unable to complete this comparison. We are aware that
this is a limitation of the present study. The significant increase
in the number of repetitions suggests that SZ subjects have
difficulties in self-monitoring and tracking abilities that are the
key in the retrieval process (Lezak et al., 2012).
The verbal and visuospatial measures (DS and SS) of
immediate recall and working memory (WM) showed similar
patterns in FES (see Figure 1). No deficit was observed on
either the verbal or visuospatial tasks assessing immediate recall
and attention (DS and SS forward). Even though the deficit in
verbal WM (DS backward) was stronger than in the spatial WM,
there was a trend of significance in SS backward (p = 0.06).
Moreover, the pattern of deviation in both tests was similar
(see Figure 1). One of the reasons for the lack of significance
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TABLE 4 | Regression model of PANSS effect (predictor) on performance in TMT B (dependent variable).
Dependent variable TMT–B Adjusted R2 SE of the estimate Durbin-Watson B SE Beta F p
Predictor variable (Model): 0.409 35.1850 1.850 12.4 <0.001
(Constant) 112,244 29,361 0.001
PANSS-N 3.766*** 0.850 0.599 <0.001
PANSS-G −2.968** 1.034 −0.388 0.007
Excluded:
PANSS-P 0.006 0.968
Stepwise multimodal linear regression in FES subjects (N = 34); PANSS, Positive and Negative Symptoms Scale (N, negative; G, general; P, positive); TMT-B, Trail Making Test –part 2;
Adjusted R2, explained variability; B, Unstandardized Coefficients beta; SE, Standard error; Beta, Standardized beta coefficient; Significance: **p < 0.01, ***p < 0.001.
TABLE 5 | Regression model of clinical and neuropsychological variables (predictors) on global functioning measured by GAF (dependent variable).
Dependent variable: GAF Adjusted R2 SE of the estimate Durbin-Watson B SE Beta F p
Predictor variable (Model): 0.587 11.407 1.954 18.775 <0.001
(Constant) 104.853 6.971 <0.001
PANSS–P −2.153*** 0.389 −0.712 <0.001
VERB 0.898* 0.388 0.298 0.030
Excluded:
PANSS–N −0.168 0.248
PANSS–G −0.105 0.461
CPZ 0.044 0.754
VIS 0.093 0.603
Stepwise multimodal linear regression in FES subjects (N = 26); GAF, Global Assessment of Functioning; PANSS, Positive and Negative Syndrome Scale (P, positive; N, negative; G,
general); CPZ, chlorpromazine equivalents; VERB, cumulative score for verbal tests; VIS, cumulative score for visuospatial tests; Adjusted R2, explained variability; B, Unstandardized
Coefficients beta; SE, Standard error; Beta, Standardized beta coefficient; Significance: *p < 0.05, ***p < 0.001.
in SS backward could be the smaller size of the study sample
producing reduced power size. Other reason might be the use
of a computerized version of the task. Because the computerized
version has not been validated, its sensitivity can be questioned.
However, computerized version of SS and its alternative, the
Corsi block tapping test, are commonly used in clinical studies
(e.g., Kessels et al., 2000; or studies reported in Lezak et al.,
2012), and they bring the advantage of administration reliability
independent of examiner bias. Despite the lack of significance
in the SS backward, the finding of impaired TMT-B (switching)
supports the assumption of visuospatial WM deficit in SZ.
Effect of Symptomatology on Cognitive
Functioning in FES
In agreement with more recent reviews and empirical reports
(Andreasen et al., 2005; Keefe and Fenton, 2007; Ventura et al.,
2009), we confirm the absence of relations between the symptoms
severity and standard cognitivemeasures, except for performance
on the Trail Making Test (TMT-B). TMT-B performance was
negatively affected by negative symptoms and positively affected
by general symptomatology. No effect of positive symptoms
was identified. Current literature describes a strong to moderate
association of cognitive functioning and negative symptoms
(O’Leary et al., 2000), whereas positive symptoms and cognitive
performance are usually independent in SZ (Addington et al.,
1991; Rossi et al., 1997; Andreasen et al., 2005). The finding
that better TMT-B performance was predicted by worse general
symptomatology could be explained by the fact that the PANSS
scale had higher inter-rater variability, particularly in the negative
and general symptomatology, which could generate distortion
in our findings. Indeed, our FES group showed higher scores
especially in some general symptoms (not reported in detail),
such as the item G4 (tension), which was previously identified
as more difficult for some raters (Khan et al., 2013). Despite
the single observation in TMT-B, in general, the cognitive
performance showed to be independent of clinical symptoms.
Effect of Pharmacological Treatment on
Cognitive Functioning in FES
In agreement with other studies (Jones et al., 2006; Keefe et al.,
2007; Lewis and Lieberman, 2008), we found no effect of atypical
antipsychotic medication (antipsychotic dosage calculated in
CPZ equivalents) on visuospatial or verbal performance, except
the phonemic verbal fluency performance. There was a negative
effect of CPZ on phonemic Verbal Fluency Test; however, this
result became non-significant after Bonferroni correction. Our
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TABLE 6 | Regression model of clinical and neuropsychological variables (predictors) on perceived quality of Physical health (dependent variable).
Dependent variable: Physical health Adjusted R2 SE of the estimate Durbin-Watson B SE Beta F p
Predictor variable (Model): 0.485 1.8198 1.753 8.234 0.001
(Constant) 17.064 1.202 <0.001
PANSS–N −0.162** 0.050 −0.520 0.004
VERB 0.173* 0.067 0.405 0.017
PANSS–P 0.150* 0.066 0.353 0.033
Excluded:
PANSS–G −0.079 0.628
CPZ −0.172 0.354
VIS −0.206 0.385
Stepwise multimodal linear regression (N = 24); Physical health, domain 1 in WHOQOL-BREF; PANSS, Positive and Negative Syndrome Scale (P, positive; N, negative; G, general); CPZ,
chlorpromazine equivalents; VERB, cumulative score for verbal tests; VIS, cumulative score for visuospatial tests; Adjusted R2, explained variability; B, Unstandardized Coefficients beta;
SE, Standard error; Beta, Standardized beta coefficient; Significance: *p < 0.05, **p < 0.01.
TABLE 7 | Regression model of clinical and neuropsychological variables (predictors) on perceived quality of Psychological health (dependent variable).
Dependent variable: Psychological health Adjusted R2 SE of the estimate Durbin-Watson B SE Beta F p
Predictor variable (Model): 0.144 2.235 1.803 4.859 0.038
(Constant) 16.214 1.013 <0.001
VERB 0.173* 0.079 0.425 0.038
Excluded:
PANSS–P 0.031 0.879
PANSS–N −0.235 0.250
PANSS–G 0.016 0.934
CPZ −0.087 0.691
VIS −0.107 0.728
Stepwise multimodal linear regression (N= 27); Psychological health, domain 2 in WHOQOL-BREF; PANSS, Positive and Negative Syndrome Scale (P, positive; N, negative; G, general);
CPZ, chlorpromazine equivalents; VERB, cumulative score for verbal tests; VIS, cumulative score for visuospatial tests; Adjusted R2, explained variability; B, Unstandardized Coefficients
beta; SE, Standard error; Beta, Standardized beta coefficient; Significance: *p < 0.05.
study implies that the impairment in visuospatial functions is
independent of the dosage of neuroleptic medication.
Clinical Factors and Neurocognition, and
their Effect on Global Functioning in
Schizophrenia Spectrum Disorder
In our FES group we did not find any associations between GAF
and VIS functions. The fact that the only visuospatial measure
that correlated with the GAF score was the Trail Making Test
B1 could be responsible for this negative finding. Moreover, the
strong association between the negative and general symptoms
toward TMT-B performance described earlier (see Section Effect
of Symptomatology on Cognitive Functioning in FES) suggests
that VIS performance, moderated by the symptomatology, might
not survive the regression analysis as an independent predictor.
Another possible explanation for this finding is the fact that GAF
1Ex post facto analysis revealed that the GAF scale is significantly correlated only
with two neurocognitive measures. Negative correlation was found in visual Trail
Making Test B (r = −0.43, p < 0.001) and positive correlation in the semantic
Verbal Fluency Test (r = 0.36, p < 0.01).
scale was constructed as a measure of psychosocial disability
in relation to symptomatology, rather than neurocognition
(Jones et al., 1995; Roy-Byrne et al., 1996). Thus, more specific
neurocognitive functions, such as VIS, might not be captured. On
the other hand, GAF was positively affected by VERB functions
(cumulative VERB score). However, VERB functioning was only
an accompanying factor of the main negative effect produced by
positive symptoms. The effect of negative symptoms reported
in previous studies (Gaite et al., 2005) was not identified as
significant in our FES sample.We assume that positive symptoms
might have amore pronounced negative effect on the functioning
of individuals’ in our FES sample than negative and general
symptoms, due to the early remission state.
In order to compare our results with previous studies, we
used the GAF as a scale of functioning recommended as a
mandatory control assessment by EGOFORS (European Group
On Functional Outcomes and Remission in Schizophrenia)
initiative (Peuskens and Gorwood, 2012). However, in our
opinion, a more ecologically valid scale to measure functioning
in relationship to individual neurocognitive domains is needed.
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TABLE 8 | Regression model of clinical and neuropsychological variables (predictors) on perceived quality of Environment (dependent variable).
Dependent variable: Environment Adjusted R2 SE of the estimate Durbin-Watson B SE Beta F p
Predictor variable (Model): 0.278 1.9072 1.986 5.425 0.013
(Constant) 15.946 1.404 <0.001
VIS −0.107** 0.037 −0.533 0.008
CPZ −0.008* 0.004 −0.392 0.043
Excluded:
PANSS—P −0.068 0.711
PANSS—N −0.141 0.495
PANSS—G 0.224 0.251
VERB −0.109 0.720
Stepwise multimodal linear regression (N = 24); Environment, domain 4 in WHOQOL-BREF; PANSS, Positive and Negative Syndrome Scale (P, positive, N, negative, G, general); CPZ,
chlorpromazine equivalents; VERB, cumulative score for verbal tests; VIS, cumulative score for visuospatial tests; Adjusted R2, explained variability; B, Unstandardized Coefficients beta;
SE, Standard error; Beta, Standardized beta coefficient; Significance: *p < 0.05.
Clinical Factors and Neurocognition, and
their Effect on Quality of Life in
Schizophrenia Spectrum Disorder
According to our results, the quality of life seems to be
related more to verbal than visuospatial cognitive measures.
Two of the four domains of WHOQOL-BREF (Physical and
Psychological health) were positively associated with overall
VERB performance, whereas only one domain (Environment)
was related to overall VIS functioning and this association was
negative. Better cumulative VIS score was associated with worse
environment quality (health services, leisure time activities, etc.).
Some previous studies have reported similar counterintuitive
negative correlations (Prouteau et al., 2005; Fiszdon et al.,
2008; Narvaez et al., 2008). This negative relation between
QOL and neurocognition is often explained with a lack of
insight (Prouteau et al., 2005; Narvaez et al., 2008) or with
an overestimation of the level of disability due to present
depressive symptoms (Bowie et al., 2007). We do not attempt
to interpret this negative relation in terms of insight, as some
other possible moderators might attenuate the relationship
between neurocognition and QOL. However, we are aware
of this discrepancy and we suggest that future research is
needed in order to clarify the character of such puzzling
results.
The WHOQOL-BREF domain of Social relationships was not
associated with any of the clinical or neurocognitive measures.
We believe that this domain might not fully reflect quality of
social relationships. This domain includes only three questions
that report on the quality of social relations, sexual life, and social
support. These items do not cover all aspects of interpersonal
relationships. Moreover, the item “Friend’s support” was reported
to be less relevant for the younger population assessed also in our
study (Dragomirecká and Bartonˇová, 2006a). WHOQOL-BREF
might therefore not be a suitable tool for the measurement of
social QOL in such a specific population.
Our choice of QOL measure, the WHOQOL-BREF, likely
also played a role in the obtained results. In general, research
findings on the relationship of neurocognition and QOL are
very heterogeneous and often report weak associations between
these two constructs (Heslegrave et al., 1997; Aksaray et al., 2002;
Fiszdon et al., 2008). One issue that has to be considered is
how other QOL questionnaires address cognition in individual
items. For example, only one question of the WHOQOL-BREF
specifically concentrates on the cognitive functioning. When we
ex post facto analyzed the correlation between this item (Q7,
quality of concentration in Psychological health domain) and
individual cognitive measures, we found a strong relationship
toward several cognitive tests, both VIS and VERB (mostly
related to processing speed, memory and executive functions)2.
This is in agreement with previous studies that highlighted the
role of executive functions (e.g., Fiszdon et al., 2008; Matsui et al.,
2008) and memory domains as the most representative measures
related to QOL. If QOL questionnaires were more focused on
cognitive functioning, we believe that the contradictory findings
could be reduced.
In terms of clinical symptomatology, out of the four
WHOQOL-BREF domains only Physical health appeared to
be significantly affected by psychiatric symptoms. As expected,
cognitive performance was not the only factor affecting subjective
quality of physical health; the severity of the negative and positive
symptoms obviously had some impact as well. Meta-analysis
by Eack and Newhill (2007) described the strongest, but still
small, association of Physical health QOL to general symptoms.
However, our study found no such association. An explanation
for the differences between our results and the previous findings
can be the fact that we assessed first psychotic episode in
schizophrenia spectrum patients and that the length of illness
might moderate the relationship between symptoms and QOL
(Eack and Newhill, 2007).
2Ex post facto analyzed relationship of Psychological health item Q7
(concentration) with individual test methods, showed positive correlation
with the AVLT test in terms of learning (r = 0.572) and delayed memory
(r = 0.508), Verbal Fluency (phonemic: r = 0.519; semantic: r = 0.457) and
Spatial Span performance (total score: r = 0.479; backwards: r = 0.445), and
similarly negative correlation with TMT processing time (part A: r = −0.432; B:
r = −0.602).
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Concluding Remarks
The studies addressing effect of cognitive deficit on global
functioning or QOL are common in current research of SZ.
However, studies that address these findings in first psychotic
episode of schizophrenia spectrum disorder and which include
complex verbal and visuospatial cognitive assessment are quite
rare. We addressed the need for such research in the present
study.
The results of the present study confirmed a deficit of
visuospatial functions in FES. This deficit is independent of
antipsychotic medication and clinical symptoms. Both global
functioning and quality of life were shown to be more related
to verbal than to visuospatial functions. Given the findings of
negative or missing effect of visuospatial deficit on WHOQOL-
BREF and GAF, the accuracy of these measures to evaluate
the impact of global cognitive deficit on everyday life in
schizophrenia could be questioned. We suggest the need for
further investigation of the association of QOL questionnaires
and GAF scale to cognitive functioning. Finally, according to
our findings, the deficit in executive and memory domains
is the most pronounced in the FES group. We suggest that
these two domains may contribute to the cumulative cognitive
performance affecting QOL and GAF scores. Further research
needs to clarify this assumption.
Limitations of the Study and Future
Directions
There are several limitations of the present study that warrant
discussion. First, the results of the study could be tempered by
the small size of the sample and consequent reduction in power
size. Despite the smaller number of participants, we were able to
demonstrate the deficit in both visuospatial and verbal cognitive
functioning in schizophrenia, and the relationship of these
abilities toward global functioning and quality of life. In order
to reveal possible effects of other variables on these relationships
(such as demography and subtypes of schizophrenia) and to
identify individual cognitive domains affecting QOL and GAF, a
larger sample size is needed.
Second, the issue of cross-sectional vs. longitudinal studies
in this area is important. The present study, although cross-
sectional, has identified some specific effects that can be
examined over a longer time period. The next step in this research
is, therefore, to track the longitudinal effect of visuospatial
functions on global functioning and QOL in schizophrenia. We
are currently conducting a follow-up assessment in our study
group 1 year after their first hospitalization to measure the
cognitive functioning in full remission state. Moreover, studies
comparing FES with chronic schizophrenia patients are limited.
To address this limitation we are assessing a chronic SZ sample in
order to analyze the influence of the illness duration on relations
between neurocognition, QOL, and GAF.
Third, the fact that the verbal and visuospatial
neuropsychological tests were not always matched in terms
of the measured cognitive domain, and for psychometric
parameters, might be another possible limiting factor. In
addition, not all test methods are validated in schizophrenia
and some of them are not standardized for Czech population
either. Measures validated in schizophrenia population might be
expected to be more sensitive when capturing a degree of deficit.
We are also aware of the fact that we don’t cover all the functions
of each cognitive domain. For example we did not include verbal
recognition in our analysis; therefore the encoding ability could
not be assessed as clearly as in the visuospatial domain. More
specific and detailed visuospatial assessment is necessary in order
to cover all domains that can be related to functional outcome
and QOL in schizophrenia spectrum disorders.
Fourth, measures of QOL and global functioning applied
in this study could be limited in terms of their association
with cognitive functioning in SZ. It would be very helpful to
compare them to other methods that might be more related
to neurocognition. For example, the Social and Occupational
Functional Assessment Scale (SOFAS) could provide a better
measurement of functional outcome that is not tied to
symptomatology. In addition, only subjective QOLwasmeasured
in this study. Objective measures of QOL are needed in
order to understand the complex relationships of psychosocial
functioning and neurocognition in SZ. According to our results
about relation of specific domains of QOL and GAF obtained
in the ex post facto measures, we suggest that these associations
should be further investigated in future research.
Finally, several neurotransmitter functions are affected by
atypical antipsychotics and our study applied only the CPZ
equivalent. Future study should also address other factors in
order to analyze the effects of medication on cognitive abilities
in greater detail.
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